Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 372.60 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2026-02-26
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2014-09-30 was 2.00K shares, a 0.00% change year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2014-06-30 was 3.00K shares, a 50.00% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2013-09-30 was 2.00K shares.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2013-06-30 was 2.00K shares.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2025 was 372.60K shares, a 4.17% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2024 was 388.82K shares, a 11.73% decline from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2023 was 440.48K shares, a 7.86% decline from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2022 was 478.07K shares, a 3.17% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 372.60K shares 10-K · filed 2026-02-26 | |||
| 2024-12-31 | 388.82K shares 10-K · filed 2025-03-03 | |||
| 2023-12-31 | 440.48K shares 10-K · filed 2024-02-29 | |||
| 2022-12-31 | 478.07K shares 10-K · filed 2023-03-01 | |||
| 2021-12-31 | 493.72K shares 10-K · filed 2022-03-11 | |||
| 2020-12-31 | 628.05K shares 10-K · filed 2021-03-15 | |||
| 2019-12-31 | 543.50K shares 10-K · filed 2020-03-16 | |||
| 2018-12-31 | 570.59K shares 10-K · filed 2019-03-15 | |||
| 2016-12-31 | 108.82K shares 10-K · filed 2017-03-15 | |||
| 2014-09-30 | 2.00K shares 10-Q · filed 2014-11-13 | 5.00K shares derived: sum of 2 quarters · filed 2014-11-13 | 2.00K shares 10-Q · filed 2014-11-13 | |
| 2014-06-30 | 3.00K shares 10-Q · filed 2014-08-13 | 3.00K shares 10-Q · filed 2014-08-13 | ||
| 2013-09-30 | 2.00K shares 10-Q · filed 2014-11-13 | 4.00K shares derived: sum of 2 quarters · filed 2014-11-13 | 9.00K shares 10-Q · filed 2014-11-13 | |
| 2013-06-30 | 2.00K shares 10-Q · filed 2014-08-13 | 12.00K shares 10-Q · filed 2014-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |